Regarding the article "Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions", by Feeley et al.
Friedlaender
Gary E
GE
D000818:Animals; D019485:Bone Morphogenetic Proteins / Q000378:metabolism*; D001859:Bone Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology* / Q000556:secondary; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism*; D045744:Cell Line, Tumor; D018450:Disease Progression; D006801:Humans; D008297:Male; D051379:Mice; D011471:Prostatic Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D023041:Xenograft Model Antitumor Assays; D000099176:Noggin Protein
D019485:Bone Morphogenetic Proteins; D002352:Carrier Proteins; D000099176:Noggin Protein